Sjstrand M, Wei C, Cook W, et al
For those experiencing severe or persistent side effects, seeking medical advice is recommended
Bioavailability refers to the amount of a substance that actually enters your bloodstream so your body can use it
As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and newer dual- or tri-receptor agonists (incretin mimetics) redefine metabolic health management, oncology clinicians increasingly face questions about their use during and after active cancer treatment
Insurance coverage and manufacturer savings programs can influence out-of-pocket expenses
The demand for GLP-1 medications like Semaglutide is so immense, and the insurance hurdles are so high, that new models of care have emerged to bridge the gap